Sign In
Buy ALDX
$1.86
+0.220 (+13.41%)
At Close: Jun 03, 2026
Wall Street Analysts Predict a 65.75% Upside in Aldeyra Therapeutics (ALDX): Here's What You Should Know
10:55am, Tuesday, 03'rd Feb 2026
The consensus price target hints at a 65.8% upside potential for Aldeyra Therapeutics (ALDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earni
Are Medical Stocks Lagging Aldeyra Therapeutics (ALDX) This Year?
10:41am, Tuesday, 03'rd Feb 2026
Here is how Aldeyra Therapeutics, Inc. (ALDX) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Passes Below 50 Day Moving Average – Time to Sell?
04:24am, Friday, 09'th Jan 2026
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX - Get Free Report) passed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $4.97 and traded as low as $4.05
Aldeyra Therapeutics: Reproxalap's March 2026 FDA Decision Is The Defining Catalyst
06:26pm, Tuesday, 30'th Dec 2025
Aldeyra's Reproxalap is the core catalyst. The FDA will make its decision on this asset by March 16, 2026, after a procedural PDUFA extension. Reproxalap's Chamber Phase 3 trial met symptom endpoints
Aldeyra Therapeutics, Inc. (ALDX) Discusses PDUFA Target Action Date Extension for Reproxalap in Dry Eye Disease Transcript
10:09am, Tuesday, 16'th Dec 2025
Aldeyra Therapeutics, Inc. (ALDX) Discusses PDUFA Target Action Date Extension for Reproxalap in Dry Eye Disease Transcript
Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease
07:30pm, Monday, 15'th Dec 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi
Aldeyra Therapeutics, Inc. (ALDX) Discusses Expansion of RASP Platform Into CNS Diseases and Update on Reproxalap for Dry Eye Transcript
03:11pm, Thursday, 13'th Nov 2025
Aldeyra Therapeutics, Inc. ( ALDX ) Discusses Expansion of RASP Platform Into CNS Diseases and Update on Reproxalap for Dry Eye November 13, 2025 8:00 AM EST Company Participants Laura Nichols - Opera
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
07:01am, Tuesday, 11'th Nov 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi
Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET
07:00am, Thursday, 06'th Nov 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated dise
Brighton Jones LLC Invests $69,000 in Aldeyra Therapeutics, Inc. $ALDX
03:32am, Sunday, 02'nd Nov 2025
Brighton Jones LLC bought a new position in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi
Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
07:01am, Wednesday, 03'rd Sep 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the European Medicines Agency (EMA) has granted Orphan Designation for ADX-2191 (methotrexat
Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa
07:01am, Tuesday, 19'th Aug 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191
